Literature DB >> 8896409

Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.

L Bi1, R Sarkar, T Naas, A M Lawler, J Pain, S L Shumaker, V Bedian, H H Kazazian.   

Abstract

Previously we created two strains of factor VIII-deficient mice by insertion of a neo gene into (1) the 3' end of exon 16 and (2) exon 17 of the factor VIII gene. Affected mice of both strains have no plasma factor VIII activity, yet are healthy with no spontaneous bleeding. Factor VIII-deficient females bred with affected males survive pregnancy and delivery. We used reverse transcriptase-polymerase chain reaction of liver RNA to characterize factor VIII mRNA processing. Factor VIII mRNA of the exon 16 knockout strain contains neo sequences plus 17 bp of intron 16 due to use of a cryptic donor site in intron 16. All factor VIII mRNA of the exon 17 knockout strain lacks exon 17 and neo sequences. In skipping exon 17, the intron 16 donor site or a cryptic donor site 46 bp 3' to the intron 16 donor site are used. Thus, factor VIII deficiency in exon 16 knockout mice is due to truncated protein, while in exon 17 knockout mice it is due to either truncated or partially deleted protein. After immunizing exon 16 knockout mice with human recombinant factor VIII, two monoclonal antibodies were obtained that recognize < 100 pg of mouse factor VIII light chain. Assay of cryoprecipitate from the plasma of affected mice failed to show factor VIII light chain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896409

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.

Authors:  Ruo-lan Gu; Liang Liu; Liang-zhi Xie; Wen-lin Gai; Si-shuo Cao; Zhi-yun Meng; Hui Gan; Zhuo-na Wu; Jian Li; Ying Zheng; Xiao-xia Zhu; Gui-fang Dou
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

2.  Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.

Authors:  C L Liu; P Ye; J Lin; D Djukovic; C H Miao
Journal:  J Thromb Haemost       Date:  2014-06       Impact factor: 5.824

Review 3.  Platelet and endothelial expression of clotting factors for the treatment of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Thromb Res       Date:  2012-03-14       Impact factor: 3.944

4.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

5.  Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.

Authors:  G L Evans; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

Authors:  Baowei Peng; Peiqing Ye; David J Rawlings; Hans D Ochs; Carol H Miao
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

7.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

8.  Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

Authors:  C D Porada; C Sanada; C R Long; J A Wood; J Desai; N Frederick; L Millsap; C Bormann; S L Menges; C Hanna; G Flores-Foxworth; T Shin; M E Westhusin; W Liu; H Glimp; E D Zanjani; J N Lozier; V Pliska; G Stranzinger; H Joerg; D C Kraemer; G Almeida-Porada
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

9.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

10.  A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.

Authors:  C Denis; N Methia; P S Frenette; H Rayburn; M Ullman-Culleré; R O Hynes; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.